19-41354744-C-A
Variant summary
Our verdict is Likely benign. Variant got -6 ACMG points: 0P and 6B. BP4BS1_SupportingBS2
The NM_030578.4(B9D2):c.484G>T(p.Gly162Cys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000052 in 1,614,004 control chromosomes in the GnomAD database, including 2 homozygotes. In-silico tool predicts a benign outcome for this variant. 14/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_030578.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -6 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
B9D2 | NM_030578.4 | c.484G>T | p.Gly162Cys | missense_variant | 4/4 | ENST00000243578.8 | NP_085055.2 | |
B9D2 | XM_011527349.3 | c.484G>T | p.Gly162Cys | missense_variant | 4/4 | XP_011525651.1 | ||
B9D2 | XM_011527350.3 | c.325G>T | p.Gly109Cys | missense_variant | 3/3 | XP_011525652.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
B9D2 | ENST00000243578.8 | c.484G>T | p.Gly162Cys | missense_variant | 4/4 | 1 | NM_030578.4 | ENSP00000243578.2 |
Frequencies
GnomAD3 genomes AF: 0.0000329 AC: 5AN: 152192Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000638 AC: 16AN: 250866Hom.: 0 AF XY: 0.0000663 AC XY: 9AN XY: 135746
GnomAD4 exome AF: 0.0000540 AC: 79AN: 1461694Hom.: 2 Cov.: 32 AF XY: 0.0000605 AC XY: 44AN XY: 727162
GnomAD4 genome AF: 0.0000328 AC: 5AN: 152310Hom.: 0 Cov.: 32 AF XY: 0.0000403 AC XY: 3AN XY: 74466
ClinVar
Submissions by phenotype
not specified Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 25, 2024 | The c.484G>T (p.G162C) alteration is located in exon 4 (coding exon 3) of the B9D2 gene. This alteration results from a G to T substitution at nucleotide position 484, causing the glycine (G) at amino acid position 162 to be replaced by a cysteine (C). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | May 11, 2022 | Variant summary: B9D2 c.484G>T (p.Gly162Cys) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 6.4e-05 in 250866 control chromosomes (gnomAD). This frequency is not significantly higher than expected for a pathogenic variant in B9D2 causing Joubert Syndrome And Related Disorders (6.4e-05 vs 0.0004), allowing no conclusion about variant significance. To our knowledge, no occurrence of c.484G>T in individuals affected with Joubert Syndrome And Related Disorders and no experimental evidence demonstrating its impact on protein function have been reported. One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation and classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. - |
Meckel-Gruber syndrome;C0431399:Familial aplasia of the vermis Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jun 01, 2022 | This sequence change replaces glycine, which is neutral and non-polar, with cysteine, which is neutral and slightly polar, at codon 162 of the B9D2 protein (p.Gly162Cys). This variant is present in population databases (rs760322583, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with B9D2-related conditions. ClinVar contains an entry for this variant (Variation ID: 1341710). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Feb 15, 2022 | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge - |
Meckel syndrome, type 10 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | New York Genome Center | Jun 26, 2020 | The homozygous c.484G>T (p.Gly162Cys) variant identified in the B9D2 gene substitutes a moderately conserved Glycine for Cystine at amino acid 162/176 (exon 4/4). This variant is found with low frequency in gnomAD(v3.0) (3 heterozygotes, 0 homozygotes; allele frequency:2.09e-5) suggesting it is not a common benign variant in the populations represented in that database. In silico algorithms do not agree on the effect of this variant, as it is predicted both Deleterious (Provean; score:-3.31) and Tolerated (SIFT; score:0.124) to the function of the canonical transcript. This variant is reported as a Variant of Uncertain Significance in ClinVar (VarID:329340) and to our current knowledge has not been reported in affected individuals in the literature. Given the lack of compelling evidence for its pathogenicity, the homozygous c.484G>T (p.Gly162Cys) variant identified in the B9D2 gene is reported here as a Variant of Uncertain Significance. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at